NYSE:DVADavita Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Davita Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $81.05 +0.41 (+0.51 %) (As of 07/3/2020 04:00 PM ET) Add Compare Share Today's Range$80.79Now: $81.05▼$82.6850-Day Range$75.56MA: $79.93▼$88.2852-Week Range$50.68Now: $81.05▼$90.15Volume880,488 shsAverage Volume1.23 million shsMarket Capitalization$9.87 billionP/E Ratio12.74Dividend YieldN/ABeta1.2 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services. As of December 31, 2018, it provided dialysis and administrative services in the United States through a network of 2,664 outpatient dialysis centers serving approximately 202,700 patients; and operated 241 outpatient dialysis centers located in 9 countries outside of the United States serving approximately 25,000 patients. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was founded in 1994 and is headquartered in Denver, Colorado.Read More Beat the Market (BTM) Rank™ 1.1 Analyst's Opinion Consensus RatingDavita has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on 2 buy ratings, 9 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $68.86, Davita has a potential downside of 15.0% from its current price of $81.05.Amount of Analyst CoverageDavita has only been the subject of 2 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesDavita has received 461 “outperform” votes. (Add your “outperform” vote.)Underperform VotesDavita has received 519 “underperform” votes. (Add your “underperform” vote.)Community SentimentDavita has received 52.96% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Davita and other stocks. Vote “Outperform” if you believe DVA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DVA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldDavita does not currently pay a dividend.Dividend GrowthDavita does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Davita insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $989,903.00 in company stock.Percentage Held by InsidersOnly 1.10% of the stock of Davita is held by insiders.Percentage Held by Institutions91.52% of the stock of Davita is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Davita are expected to grow by 5.38% in the coming year, from $6.13 to $6.46 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Davita is 12.74, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 16.15.Price to Earnings Ratio vs. SectorThe P/E ratio of Davita is 12.74, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 24.44.Price to Earnings Growth RatioDavita has a PEG Ratio of 1.45. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDavita has a P/B Ratio of 4.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.1Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.27 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Miscellaneous health & allied services, not elsewhere classified Sub-IndustryHealth Care Services SectorMedical Current SymbolNYSE:DVA Previous Symbol CUSIP23918K10 CIK927066 Webwww.davita.com Phone720-631-2100Debt Debt-to-Equity Ratio5.24 Current Ratio1.81 Quick Ratio1.77Price-To-Earnings Trailing P/E Ratio12.74 Forward P/E Ratio13.22 P/E Growth1.45 Sales & Book Value Annual Sales$11.39 billion Price / Sales0.87 Cash Flow$11.27 per share Price / Cash Flow7.19 Book Value$18.10 per share Price / Book4.48Profitability EPS (Most Recent Fiscal Year)$5.40 Net Income$810.98 million Net Margins7.85% Return on Equity32.45% Return on Assets5.03%Miscellaneous Employees65,000 Outstanding Shares121,800,000Market Cap$9.87 billion Next Earnings Date8/6/2020 (Estimated) OptionableOptionable DVA Rates by TradingView Receive DVA News and Ratings via Email Sign-up to receive the latest news and ratings for DVA and its competitors with MarketBeat's FREE daily newsletter. Davita (NYSE:DVA) Frequently Asked Questions How has Davita's stock been impacted by COVID-19 (Coronavirus)? Davita's stock was trading at $74.87 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DVA stock has increased by 8.3% and is now trading at $81.05. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Davita? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Davita in the last year. There are currently 9 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Davita. When is Davita's next earnings date? Davita is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Davita. How were Davita's earnings last quarter? Davita Inc (NYSE:DVA) posted its quarterly earnings data on Tuesday, May, 5th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.47 by $0.36. The company had revenue of $2.84 billion for the quarter, compared to analysts' expectations of $2.84 billion. Davita had a return on equity of 32.45% and a net margin of 7.85%. Davita's revenue was up 3.6% on a year-over-year basis. During the same quarter last year, the business posted $0.91 earnings per share. View Davita's earnings history. What guidance has Davita issued on next quarter's earnings? Davita issued an update on its FY20 earnings guidance on Tuesday, May, 5th. The company provided earnings per share guidance of $5.75-6.25 for the period, compared to the Thomson Reuters consensus estimate of $6.01. The company issued revenue guidance of $11.5-11.7 billion, compared to the consensus revenue estimate of $11.65 billion. What price target have analysts set for DVA? 11 brokerages have issued 12 month target prices for Davita's stock. Their forecasts range from $57.00 to $90.00. On average, they expect Davita's stock price to reach $68.86 in the next year. This suggests that the stock has a possible downside of 15.0%. View analysts' price targets for Davita. Has Davita been receiving favorable news coverage? News articles about DVA stock have been trending negative recently, according to InfoTrie. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Davita earned a daily sentiment score of -2.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the next several days. View the latest news about Davita. Who are some of Davita's key competitors? Some companies that are related to Davita include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Chemed (CHE), Amedisys (AMED), LHC Group (LHCG), AMN Healthcare Services (AMN), MEDNAX (MD), R1 RCM (RCM), CorVel (CRVL), The Providence Service (PRSC), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG). View all competitors. What other stocks do shareholders of Davita own? Based on aggregate information from My MarketBeat watchlists, some companies that other Davita investors own include CA (CA), BlackRock (BLK), Chipotle Mexican Grill (CMG), Endologix (ELGX), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), United Rentals (URI), AutoZone (AZO), Walt Disney (DIS) and Gilead Sciences (GILD). Who are Davita's key executives? Davita's management team includes the following people: Mr. Kent J. Thiry, Chairman & CEO (Age 63)Mr. Joel Ackerman, Chief Financial Officer (Age 54)Mr. James K. Hilger, Chief Accounting Officer (Age 57)Ms. Kathleen Alyce Waters, Chief Legal Officer (Age 51)Mr. Javier J. Rodriguez, Chief Exec. Officer of DaVita Kidney Care (Age 48) What is Davita's stock symbol? Davita trades on the New York Stock Exchange (NYSE) under the ticker symbol "DVA." How do I buy shares of Davita? Shares of DVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Davita's stock price today? One share of DVA stock can currently be purchased for approximately $81.05. How big of a company is Davita? Davita has a market capitalization of $9.87 billion and generates $11.39 billion in revenue each year. The company earns $810.98 million in net income (profit) each year or $5.40 on an earnings per share basis. Davita employs 65,000 workers across the globe. What is Davita's official website? The official website for Davita is www.davita.com. How can I contact Davita? Davita's mailing address is 2000 16TH STREET, DENVER CO, 80202. The company can be reached via phone at 720-631-2100 or via email at [email protected] This page was last updated on 7/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
